Waleed Najeeb, MD
Pulmonary Disease · Glendale, WINPI 1407879877
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,962 of the $26,426 with a category attached, or 71.8%. 58 manufacturers reported payments, led by Gilead at 28.8% of the total. Reporting peaked in 2022 at $9,864 and has fallen 74.6% since, to $2,501 in 2025. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,161 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$8K
- AstraZeneca$3K
- AbbVie$2K
- Boehringer Ingelheim$2K
- Johnson & Johnson$1K
- GSK$1K
- plus $10K from 52 others
Across 1 payment — averaging $9600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rivanna Medical, Inc$10K
What the payments were for
- Consulting fees$5,56021%
- Travel & lodging$1,1524%
- Food & beverage$18,96272%
- Education$7523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,426 in reported general payments places this provider in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 213 | $145,355 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 207 | $142,561 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 206 | $115,272 |
| EliquisApixaban | 111 | $81,999 |
| FarxigaDapagliflozin Propanediol | 87 | $78,859 |
| LinzessLinaclotide | 99 | $68,564 |
| Breo ElliptaFluticasone/Vilanterol | 156 | $68,242 |
| Dupixent PenDupilumab | 16 | $68,168 |
| JardianceEmpagliflozin | 85 | $64,421 |
| XareltoRivaroxaban | 94 | $60,166 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 109 | $58,879 |
| CreonLipase/Protease/Amylase | 31 | $55,595 |
| JanuviaSitagliptin Phosphate | 48 | $44,883 |
| TezspireTezepelumab-Ekko | 11 | $44,371 |
| JanumetSitagliptin Phos/Metformin Hcl | 45 | $37,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga, Tezspire, Symbicort, Nexium | $3,123 | $309,178450 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,159 | $272,476478 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $1,541 | $222,611359 claims |
| AbbVieLinzess, Creon | $2,130 | $124,158130 claims |
| MerckJanuvia, Janumet | $471 | $82,70793 claims |
| PfizerEliquis | $1,009 | $81,999111 claims |
| Johnson & JohnsonXarelto | $1,310 | $60,16694 claims |
| Novo NordiskOzempic | $445 | $24,17326 claims |
| BayerKerendia | $557 | $18,26623 claims |
| Astellas Pharma US IncMyrbetriq | $621 | $17,63734 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $727 | $14,91319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Glendale
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
- Alfred HabelKenosha$194K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.